Twelve-year experience of nevirapine use: Benefits and convenience for long-term management in a french cohort of HIV-1-infected patients

HIV Clinical Trials

Volumn 11, Issue 2, 2010, Pages 110-117

  Reliquet, V ^a   Allavena, C ^a   Morineau Le Houssine, P ^a   Mounoury, O ^a   Raffi, F ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Nevirapine; Persistency; Potency

Indexed keywords

EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FOLLOW UP; FRANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FAILURE; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SKIN MANIFESTATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 77953564689     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1102-110     Document Type: Article

References (23)

1. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother. 2009;64(5):910-928.
2. Pierone G Jr, Mieras J, Martin A, Urban T. Seven-year follow-up on lopinavir/ ritonavir monotherapy. J Int Assoc Physicians AIDS Care. 2009;8(3):191-192.
3. Willig J, Abroms S, Westfall A, et al. Increased regimen durability in the era of once-daily fi xed-dose combination antiretroviral therapy. AIDS 2008;22:1951-1960.
4. Bartlett JA, Fath MJ, Demasi R, et al. An updated systematic overview of triple combination therapy in antiretroviralnaïve HIV-infected adults. AIDS 2006; 20(16):2051-2064.
5. Riddler SA, Haubrich R, DiRienzo AG, et al. AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095-2106.
6. Franssen R, Sankatsing RR, Hassink E, et al. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol. 2009;29(9):1336-1341.
7. van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profi les in antiretroviral- therapy-naïve patients infected with HIV-1. PLoS Med. 2004;1(3):e73.
8. Parienti JJ, Massari V, Rey D, et al. Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study. Clin Infect Dis. 2007;45(2):263-266. (Pubitemid 47041021)
9. Bonjoch A, Paredes R, Domingo P, et al. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Res Hum Retroviruses. 2006;22(4):321-329
10. Colafi gli M, Di Giambenedetto S, Bracciale L, et al. Longterm follow-up of nevirapine-treated patients in a singlecentre cohort. HIV Med. 2009;10(8):461-469.
11. Rodríguez-Arrondo F, Aguirrebengoa K, Portu J, et al. Long-term effectiveness and safety outcomes in HIV-1- infected patients after a median time of 6 years on nevirapine. Curr HIV Res. 2009 Sep;7(5):526-532.
12. Mocroft A, Staszewski S, Weber R, et al. EuroSIDA study group. Risk discontinuation of nevirapine due to toxicities in antiretroviral-naïve and -experienced HIV-infected patients with high and low CD4+T cell counts. Antivir Ther. 2007;12:325-333.
13. Kesselring A, Wit F, Sabin C et al. Risk factors for treatment- limiting toxicities in patients starting nevirapine containing antiretroviral therapy. AIDS 2009;23:1689-1699.
14. Cooper Cl and Van Heeswijk RPG. Once-daily nevirapine dosing: a pharmacokinetics, effi cacy and safety review. HIV Med. 2007;8:1-7.
15. Van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of fi rst-line antiretroviral therapy with regimens including nevirapine, efavirenz or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet. 2004;363:1253-1263.
16. Soriano V, Köppe S, Mingrone H, et al. Prospective comparison of nevirapine and atazanavir/ritonavir both combined with tenofovir DF/emtricitabine in treatment-naïve HIV-1 infected patients: ARTEN study week 48 results. In: Program and abstracts from the Fifth IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2009; Cape Town, South Africa. Abstract LBPE07.
17. Podzamczer D, Olmo M, Sanz J, et al. Safety of switching nevirapine twice daily to nevirapine once daily in virologically suppressed patients. J Acquir Immune Defi c Syndr. 2009 ;50(4):390-396.
18. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodefi ciency in HIVassociated atherosclerosis. AIDS. 2009;23(9):1059-1067.
19. Rodriguez-Arrondo F, Aguirrebengoa K, Portu J, et al. Long-term effectiveness and safety outcomes in HIV-1- infected patients after a median time of 6 years on nevirapine. Curr HIV Res. 2009;7(5):526-532.
20. Mastan S, Kumar KE. Infl uence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models. Diabetol Metab Syndr. 2009;1(1):15.
21. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65-70.
22. Kashuba A. Genital compartmentalization of orally and topically administered antiretrovirals. In: Program and abstracts from the 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, Massachusetts. Abstract 95.
23. Bonora S, Nicastri E, Calcagno A, et al. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol. 2009;81(3):400-405.